Metabolic alterations, including deficits in acylcarnitines, have previously been reported in brains of a transgenic mouse model of AD bearing mutated APP and PS1 transgenes, in which early brain amyloid deposition and cognitive impairment occur (36). This evidence concerns the gene APP and Alzheimer disease.